Moderna-Merck Breakthrough Brings Hope for Cancer Treatment Revolution

Moderna and Merck's breakthrough in cancer treatment has opened up new avenues for treatment that doctors hope will work against many types of tumors. Unlike chemotherapy, which kills both healthy and cancerous cells, or immunotherapy, which revs up the immune system, personalized cancer vaccines train the immune system to specifically target mutations found only on a person's tumor.

The success of Merck and Moderna's personalized cancer vaccine designed to keep melanoma at bay has led to several large trials underway in non-small cell lung cancers that have been surgically removed. The companies are also studying the combination in mid-stage trials in patients with bladder and kidney cancers as well as in early-stage trials in pancreatic and stomach cancers.

Moderna President Stephen Hoge told Reuters that numerous trial results are expected in the next year or two, including the colon cancer trial, which is expected to release its results in 2027, and the pancreatic trial, which will follow in 2031. Dr. Ryan Sullivan, director of the Center for Melanoma at Mass General Brigham Cancer Institute, said that this positive study has hope (and likely investment to follow) that these approaches may change the way we treat cancer more broadly.